Scarica l'app Stockscreener
9.08
2.99%
-0.28
Dopo l'orario di chiusura:
9.10
0.02
+0.22%
Precedente Chiudi:
$9.36
Aprire:
$9.1
Volume 24 ore:
173.21K
Relative Volume:
1.74
Capitalizzazione di mercato:
$3.07B
Reddito:
$417.75M
Utile/perdita netta:
$32.27M
Rapporto P/E:
93.13
EPS:
0.0975
Flusso di cassa netto:
-
1 W Prestazione:
-10.54%
1M Prestazione:
-31.83%
6M Prestazione:
-48.14%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$8.93
$9.15
Intervallo di 1 settimana:
$8.93
$9.75
Portata 52W:
$8.93
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Nome
Telix Pharmaceuticals Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta TLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
9.08 | 3.16B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-05 | Iniziato | Wedbush | Outperform |
| 2024-11-15 | Iniziato | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Borsa (TLX) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - Morningstar
Telix stock plunges after FDA issues Complete Response Letter - Investing.com
Telix stock plunges after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Telix Shares Drop After FDA Issues Complete Response Letter - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - cnhinews.com
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire Inc.
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm - Barchart.com
Telix Pharmaceuticals faces SEC subpoena, investors encouraged to contact Bragar Eagel & Squire. - AInvest
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm - Morningstar
Investigation into Telix Pharmaceuticals Ltd. Allegations of Misleading Business Information - AInvest
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX - Business Wire
Telix Pharmaceuticals under SEC investigation, shareholder lawsuit launched. - AInvest
Regulatory Scrutiny and Biotech Volatility: Lessons from Telix Pharmaceuticals' SEC Subpoena - AInvest
Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet. - AInvest
Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct. - AInvest
Pomerantz LLP investigates Telix Pharmaceuticals on securities fraud claims. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent
Telix Pharmaceuticals under investigation for potential securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Shareholders to Connect - ACCESS Newswire
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Telix Pharmaceuticals under investigation for securities fraud, ADR price falls. - AInvest
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Investors to Connect - ACCESS Newswire
Telix Pharmaceuticals under investigation for alleged securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Telix Announces H1 2025 Earnings Date: Global Investors Briefing Set for August 21 - Stock Titan
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Telix Pharmaceuticals Limited (TLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan
Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan
H.C. Wainwright initiates Telix Pharmaceuticals stock with Buy rating on radiotherapy portfolio - Investing.com
FDA Approval: Illuccix Expansion Could Add 20,000 Annual Prostate Cancer Scans - Stock Titan
Revolutionary Dual-Isotope Cancer Imaging: Telix Unveils AlFluor Platform with Phase 3 Trial Success - Stock Titan
Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan
Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan
5 of the best ASX 200 shares to buy in June - The Motley Fool Australia
Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Pharmaceuticals Ltd Adr Azioni (TLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):